Onychomycosis - Epidemiology Forecast - 2032

This ‘Onychomycosis - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of onychomycosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan and China.

Onychomycosis: Disease Understanding

Onychomycosis Overview

Onychomycosis is a fungal nail infection that causes discoloration and thickening of the affected nail plate. It was initially caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by non-dermatophyte molds (NDMs) are more prevalent, especially in warmer climates. Onychomycosis caused by dermatophytes is called tinea unguium. The term onychomycosis encompasses not only dermatophytes but also yeasts and saprophytic mold infections. Although it can infect both fingernails and toenails, Onychomycosis of the toenail is more prevalent.

Onychomycosis is classified into subtypes based on the invasion pattern. Distal subungual onychomycosis (DSO) is the most common subtype and occurs when the fungus invades the distal aspect of the nail plate. In superficial white onychomycosis (SWO), fungi invade the most superficial layers of the nail plate. Proximal subungual onychomycosis (PSO) is caused by the infecting organism invading from the undersurface of the proximal nail fold, and the infection then progresses distally. Endonyx onychomycosis (EO) occurs with the fungal invasion of the nail plate without infection of the nail bed. Total dystrophic onychomycosis (TDO) represents end-stage onychomycosis and may follow any other subtypes. Secondary onychomycosis (SO) is a non-fungal nail condition (i.e., psoriasis) with a secondary fungal infection, clinically approximating both the fungal and non-fungal nail conditions.

The treatment of onychomycosis involves the usage of oral antifungals, topical antifungals, and devices. Oral antifungals have higher cure rates than topical treatments but have adverse side effects such as hepatotoxicity and drug interactions. Topical treatments have less serious side effects but generally result in lower cure rates and longer treatment regimens.

Hence, treatment aims to prevent drug interactions and potential hepatotoxicity. The prime focus in the treatment of onychomycosis is to achieve superior efficacy and less time-consuming therapies with better nail bed penetration.

Onychomycosis: Epidemiology

The onychomycosis epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted onychomycosis epidemiology segmented as the diagnosed prevalent cases of onychomycosis, Gender-specific cases of onychomycosis, Age-specific cases of onychomycosis, Type-specific cases of onychomycosis and Severity-specific cases of onychomycosis. The report includes the diagnosed prevalent scenario of onychomycosis symptoms covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2019 to 2032.

Country-wise Onychomycosis Epidemiology

The epidemiology segment also provides the onychomycosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

The total prevalent patient population of onychomycosis in the 7MM countries was close to 121,600,000 cases in 2021.

As per the estimates, the US had the highest total prevalent patient population of onychomycosis population in 2021. Among the EU5 countries, France had the highest total prevalent patient population of onychomycosis with more than 11,600,000 cases, followed by Germany in 2021. On the other hand, Spain had the lowest total prevalent patient population of onychomycosis close to 1,200,000 cases in 2021.

Scope of the Report

• Onychomycosis report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns
• The onychomycosis epidemiology report and model provide an overview of the risk factors and global trends of onychomycosis in the 7MM + China
• The report provides insight into the historical and forecasted patient pool of onychomycosis covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
• The report helps recognize the growth opportunities in the 7MM + China concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of onychomycosis
• The report provides the segmentation of the onychomycosis epidemiology by diagnosing prevalent cases of onychomycosis in 7MM + China
• The report provides the segmentation of the Onychomycosis epidemiology by age-specific cases of onychomycosis in 7MM + China
• The report provides the segmentation of the onychomycosis epidemiology by severity-specific cases of onychomycosis in 7MM + Chin
• The report segments the Onychomycosis epidemiology by types-specific cases of onychomycosis in 7MM + China

Report Highlights

• 11-year Forecast of Onychomycosis Epidemiology
• 7MM + China Coverage
• Prevalent cases of Onychomycosis
• Type-specific cases of Onychomycosis
• Age-specific cases of Onychomycosis
• Severity- specific cases of Onychomycosis

KOL Views

The publisher interviews KOLs and obtain SME's opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM + China for the patient population with onychomycosis?
• What are the key findings of the onychomycosis epidemiology across 7MM + China, and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients with onychomycosis across the 7MM + China during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR is the patient population expected to grow in the 7MM + China forecast period (2019-2032)?
• What are the disease risk, burdens, and unmet needs of onychomycosis?
• What are the currently available treatments for onychomycosis?

Reasons to Buy

Onychomycosis Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global onychomycosis market
• Quantify patient populations in the global onychomycosis market to improve product design, pricing, and launch plans
• Understand the magnitude of the onychomycosis population by its diagnosed prevalent cases
• Understand the magnitude of the onychomycosis population by its age-specific cases.
• Understand the magnitude of the onychomycosis population by its type-specific cases of onychomycosis
• Understand the magnitude of the onychomycosis population by severity- specific cases of onychomycosis
• The onychomycosis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Onychomycosis epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

• Patient segmentation
• Disease risk and burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• China

Study Period: 2019-2032